Ropeginterferon alfa-2b

PubChem compound: 86278347

Therapeutic indications

Ropeginterferon alfa-2b is indicated for:

Polycythaemia vera

Population group: only adults (18 years old or older)

Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ropeginterferon alfa-2b is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

End stage renal disease

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Decompensated cirrhosis of the liver

at least one of
Hepatic failure stage III
Hepatic failure stage IV

Pre-existing thyroid disease

Disorder of thyroid gland

Existence or history of severe psychiatric disorders

at least one of
Mental disorder
H/O: psychiatric disorder

Severe pre-existing cardiovascular disease, recent stroke or myocardial infarction

at least one of
Cardiovascular disorder
CVA - Cerebrovascular accident
Myocardial infarction

History or presence of autoimmune disease

at least one of
Autoimmune disease
History of autoimmune disorder of endocrine system

Immunosuppressed transplant recipients

at least one of
Transplant present
Immunosuppressive therapy for transplant
Patient immunosuppressed

Telbivudine

Telbivudine

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: BESREMI Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈